Support and management for survivors of stem cell transplantation
AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation
This study is testing a new support program for people who have had stem cell transplants to see if it can help them feel better and improve their quality of life.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Rigshospitalet, Denmark Academic / other |
| Locations | 1 site (Copenhagen) |
| Trial ID | NCT06281496 on ClinicalTrials.gov |
What this trial studies
This study evaluates a comprehensive intervention aimed at addressing late effects experienced by survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It is designed as a two-arm randomized controlled trial, including an internal pilot phase, to assess the impact of a multidisciplinary approach on health-related quality of life. Participants will be randomly assigned to either an intervention group receiving the AlloCare program or a control group. The goal is to improve survivorship-specific outcomes for these patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients over 18 years who have undergone allo-HSCT and are currently in outpatient follow-up without recurrent disease.
Not a fit: Patients with recurrence of disease or those requiring additional cancer treatment will not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly enhance the quality of life for survivors of allo-HSCT by effectively managing late effects.
How similar studies have performed: While there have been studies addressing survivorship in cancer patients, this specific multimodal approach for allo-HSCT survivors is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (age\> 18 years) treated with myeloablative or non-myeloablative HSCT in outpatient follow-up without recurrent disease are eligible for inclusion. Exclusion Criteria: * Patients with recurrence or subsequent malignancy requiring cancer treatment or lack of access to email and the Internet will be excluded.
Where this trial is running
Copenhagen
- Rigshospitalet — Copenhagen, Denmark (Recruiting)
Study contacts
- Principal investigator: Mette Schaufuss Engedal, MSc — Rigshospitalet. Department of Hematology. Denmark
- Study coordinator: Mette Schaufuss Engedal, MSc
- Email: mette.schaufuss.engedal@regionh.dk
- Phone: +45 51896699
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.